titinisoform
express
titin
phosphoryl
myocardi
fibrosi
studi
patient
sever
symptomat
aortic
stenosi
patient
group
classic
highgradi
normalflow
preserv
eject
fraction
ef
paradox
lowflow
lowgradi
preserv
ef
reduc
ef
nonfail
donor
heart
serv
control
associ
increas
fibrosi
titinisoform
switch
toward
compliant
total
sitespecif
titin
hypophosphoryl
compar
control
heart
subtyp
reveal
titin
matrix
alter
extent
myocardi
remodel
paradox
less
sever
subtyp
thu
explain
unfavor
prognosi
ever
symptomat
aortic
stenosi
common
cardiac
diseas
associ
poor
prognosi
absenc
heart
valv
replac
chronic
elev
afterload
induc
left
ventricular
lv
hypertrophi
increas
myocardi
stiff
impair
relax
myocardi
remodel
associ
progress
dyspnea
common
symptom
poor
prognosi
patient
sever
highgradi
normalflow
preserv
eject
fraction
classic
benefit
high
probabl
aortic
valv
replac
howev
hemodynam
type
lowflow
lowgradi
sever
preserv
eject
fraction
ef
paradox
aortic
stenosi
reduc
eject
fraction
asref
occur
case
probabl
due
advanc
myocardi
remodel
posit
effect
aortic
valv
replac
uncertain
patient
particular
pathophysiolog
paradox
fulli
understood
controversi
whether
mere
moder
form
favor
prognosi
advanc
form
could
pseudosever
due
inaccuraci
measur
inconsist
guidelin
could
true
associ
pronounc
myocardi
stiffen
sever
intrins
myocardi
damag
impair
relax
therefor
wors
prognosi
classic
patholog
myocardi
relax
stiff
determin
part
fibrosi
recent
giant
sarcomer
protein
titin
emerg
main
contributor
myocardi
relax
stiff
titin
properti
sever
alter
heart
failur
includ
titin
express
major
isoform
adult
heart
stiff
compliant
isoform
recent
year
grow
evid
titin
isoform
switch
toward
compliant
isoform
variou
cardiac
diseas
exampl
heart
failur
reduc
preserv
ef
isoform
transit
may
compensatori
counteract
increas
stiffen
myocardi
fibrosi
contrast
patient
clear
whether
titin
isoform
switch
toward
addit
studi
titin
isoform
express
differ
hemodynam
subtyp
phosphoryl
titin
anoth
paramet
determin
myocardi
passiv
stiff
likewis
studi
hemodynam
subtyp
knowledg
sitespecif
titin
phosphoryl
never
investig
human
would
import
measur
particular
mechan
activ
region
within
titin
spring
present
isoform
sequenc
prolineglutamatevalinelysinerich
pevk
region
stiff
segment
alter
becom
phosphoryl
dephosphoryl
present
studi
investig
titinisoform
express
totaltitin
sitespecif
phosphoryl
degre
fibrosi
endomyocardi
biopsi
sampl
patient
compar
nonfail
donor
heart
sampl
moder
valv
regurgit
stenosi
previou
cardiac
surgeri
previou
myocardi
infarct
previou
myocardi
infarct
defin
accord
current
recommend
coronari
angiographi
perform
preoper
coronari
heart
diseas
diagnos
coronari
arteri
stenosi
presenc
coronari
arteri
occlus
includ
subclin
consid
exclus
criterion
studi
patient
gave
written
consent
particip
studi
studi
protocol
approv
local
ethic
committe
approv
use
pevk
except
gener
immunoglob
himmelstadt
germani
antibodi
made
eurogentec
brussel
belgium
measur
titin
myosin
heavi
chain
mhc
ratio
coomassiestain
agaros
gel
prepar
note
substanti
number
biopsi
reveal
bare
measur
signal
titin
isoformphosphoryl
analysi
probabl
due
fact
biopsi
materi
sometim
contain
low
number
cardiomyocyt
wherea
fibrot
region
abund
band
visual
use
imag
clinic
followup
clinic
echocardiograph
followup
evalu
perform
month
time
patient
die
due
acut
cardiogen
shock
n
sepsi
n
ventricular
fibril
n
heart
pump
failur
n
mortal
rate
signific
differ
outcom
patient
without
coronari
arteri
bypass
graft
p
surviv
patient
nyha
function
class
improv
aortic
mean
gradient
valvuloarteri
imped
z
lv
mass
index
decreas
ava
increas
significantli
tabl
among
differ
subgroup
signific
differ
found
lvef
aortic
mean
gradient
tabl
surviv
rate
patient
classic
patient
asref
patient
paradox
although
differ
surviv
signific
trend
toward
wors
surviv
patient
paradox
endomyocardi
biopsi
significantli
case
sever
fibrosi
found
patient
sever
control
group
sever
nomild
fibrosi
n
moder
fibrosi
n
sever
fibrosi
n
vs
control
group
nomild
fibrosi
n
p
adjust
age
sex
aortic
stenosi
predictor
degre
fibrosi
degre
myocardi
fibrosi
appear
similar
among
patient
classic
paradox
asref
figur
patient
without
coronari
heart
diseas
signific
differ
degre
fibrosi
coronari
arteri
diseas
mild
fibrosi
n
moder
fibrosi
n
sever
fibrosi
n
vs
coronari
arteri
diseas
nomild
fibrosi
n
moder
fibrosi
n
sever
fibrosi
n
p
compar
subgroup
donor
group
median
first
quartil
third
quartil
valu
mean
ae
sd
ca
vs
asref
p
vs
pa
p
indic
comparison
baselin
paramet
paramet
followup
abbrevi
tabl
tabl
figur
phosphoryl
titin
spring
element
affect
cardiomyocyt
myocardi
passiv
stiff
phosphoserin
within
measur
known
phosphoryl
protein
kinas
pk
extracellular
signalregul
protein
kinas
cgmpactiv
pkg
pkg
pka
dephosphoryl
protein
phosphatas
wherea
phosphoserin
within
pevk
domain
phosphoryl
pkca
versu
donor
sampl
differ
median
phosphoryl
observ
figur
use
multivari
analysi
aortic
stenosi
age
found
predict
phosphoryl
titin
phosphosit
p
subgroup
pa
show
trend
hypophosphoryl
compar
donor
heart
ca
wherea
asref
subgroup
significantli
hypophosphoryl
versu
donor
tabl
figur
summari
pkapkgdepend
phosphoserin
within
human
hypophosphoryl
explain
part
total
titin
phosphoryl
deficit
versu
nonfail
control
heart
mannwhitney
u
test
reveal
statist
signific
differ
control
heart
patient
p
c
comparison
made
studi
patient
subgroup
use
kruskalw
test
p
post
hoc
multipl
pairwis
comparison
reveal
signific
differ
control
group
paradox
p
aortic
studi
examin
patient
sever
symptomat
underw
surgic
aortic
valv
replac
signific
differ
subgroup
term
clinic
symptom
ava
howev
hemodynam
analysi
reveal
fundament
differ
classic
highgradi
normalflow
paradox
lowflow
lowgradi
preserv
lv
eject
fraction
reduc
ef
particular
signific
differ
aortic
mean
gradient
stroke
volum
valvuloarteri
imped
z
lvef
bnp
tabl
trend
toward
wors
outcom
observ
patient
paradox
aortic
valv
replac
surviv
compar
classic
trend
consist
earlier
find
myocardi
fibrosi
myocardium
known
character
increas
cell
mass
increas
fibrosi
studi
confirm
patient
sever
symptomat
signific
myocardi
fibrosi
patient
paradox
show
degre
fibrosi
similar
patient
classic
asref
figur
find
consist
herrmann
et
al
examin
differ
form
underscor
view
paradox
diseas
sever
intrins
myocardi
damag
diverg
publish
data
exist
regard
ratio
compliant
titin
isoform
stiffer
isoform
patient
one
studi
demonstr
reduc
express
ratio
patient
compar
donor
heart
anoth
studi
report
signific
alter
titinisoform
composit
patient
versu
healthi
heart
yet
anoth
studi
patient
group
detect
signific
shift
titinisoform
express
ratio
toward
compliant
reason
diverg
result
unknown
investig
largest
number
patient
yet
titinisoform
express
patient
group
found
signific
shift
toward
compliant
titin
isoform
versu
nonfail
donor
heart
sampl
figur
magnitud
direct
isoform
transit
similar
seen
endstag
fail
human
heart
ischem
dilat
cardiomyopathi
compar
nonfail
donor
heart
hypophosphoryl
titin
cardiacspecif
element
human
heart
failur
anim
model
heart
failur
preserv
ef
studi
also
show
increas
ratio
phosphoryl
phosphoryl
human
heart
failur
reduc
preserv
eject
fraction
titin
contribut
modul
isoform
variat
phosphoryl
splice
factor
respons
gener
isoform
larger
compliant
smaller
isoform
titin
phosphoryl
occur
multipl
site
pevk
segment
figur
tabl
surviv
postir
stzinduc
diabet
mice
compar
noninsulin
treat
mice
surviv
vs
p
figur
tabl
supplement
figur
contrast
decreas
surviv
postir
insulinand
noninsulintr
dbdb
mice
surviv
vs
p
figur
tabl
supplement
figur
suggest
contribut
wors
outcom
myocardi
ischemiareperfus
ir
differ
respons
insulin
therapi
possibl
due
baselin
insulin
level
andor
insulin
sensit
figur
level
decreas
despit
progress
hyperglycemia
euglycemia
min
support
insulin
infus
rather
glucos
level
direct
caus
reduct
level
figur
support
evid
patient
patient
variou
form
exogen
insulin
therapi
low
insulin
level
observ
invers
correl
circul
plasma
level
insulin
figur
small
pilot
myocardi
function
first
compar
myocardi
infarct
size
respons
ir
wt
dbdb
mice
figur
mention
previou
text
observ
significantli
increas
infarct
size
diabet
heart
figur
dbdb
mice
week
prior
ir
observ
signific
restor
cardiac
level
figur
serv
control
reduct
infarct
size
figur
increas
infarct
size
dm
mice
low
rescu
exogen
restor
level
support
myocardi
protect
role
notabl
also
observ
signific
reduct
plasma
insulin
level
fast
glucos
level
intraven
deliveri
dbdb
mice
figur
could
contribut
decreas
infarct
size
dm
mice
demonstr
cardiacspecif
effect
use
cardiacspecif
overexpress
mous
model
figur
cmyc
known
downstream
akt
previous
demonstr
cmyc
neg
regul
wang
et
al
wt
mice
mice
cardiomyocytespecif
overexpress
heart
lysat
dbdb
mice
control
mimic
life
technolog
mgkg
deliveri
abbrevi
figur
heart
report
target
bim
cardiomyocyt
target
transcript
factor
kinas
eno
endotheli
cell
vascular
system
found
target
chitinas
limit
vascular
inflamm
matrix
macrophag
retard
atherosclerot
plaqu
progress
previous
demonstr
high
glucos
level
also
reduc
endothelium
predispos
thrombosi
togeth
high
glucos
high
insulin
observ
dramat
lead
sever
reduct
level
enlarg
infarct
promot
apoptosi
excess
oglcnacyl
figur
data
suggest
overload
insulin
detriment
myocardi
function
reduc
protect
particularli
heart
wang
et
al
also
part
primir
cluster
togeth
increas
express
also
associ
cardiac
dysfunct
previous
au
tetrahydrobiopterin
essenti
cofactor
product
limit
endogen
tetrahydrobiopterin
reduc
bioavail
enhanc
oxid
stress
impair
vascular
function
oral
supplement
tetrahydrobiopterin
therapeut
challeng
rapidli
oxid
vivo
author
demonstr
reduc
nitric
oxid
bioavail
correl
impair
cardiovascular
function
extrem
labil
challeng
develop
therapeut
agent
howev
bioavail
could
enhanc
pharmacolog
target
endogen
regulatori
pathway
tetrahydrobiopterin
essenti
cofactor
product
synthes
gtp
complex
feedback
regulatori
protein
gfrp
dietari
amino
acid
lphenylalanin
activ
complex
elev
vascular
thu
rais
endotheli
bh
level
suggest
strategi
maintain
healthi
product
bioavail
level
endothelium
support
intraarteri
administr
bh
improv
endotheli
dysfunct
patient
hypertens
coronari
arteri
diseas
hypercholesterolemia
howev
due
unstabl
natur
oral
administ
bh
analogu
sapropterin
limit
efficaci
improv
vascular
hemodynam
therefor
strategi
rais
endogen
bh
bioavail
level
endothelium
desir
bh
synthes
gtp
reaction
commit
step
mediat
gtp
modul
express
shown
regul
bh
cardiovascular
function
subject
feedforward
regul
lphenylalanin
lphe
via
alloster
protein
interact
feedback
regulatori
protein
gfrp
complex
oper
human
oral
challeng
lphe
lead
rise
plasma
biopterin
level
correl
bh
effect
attenu
patient
lossoffunct
mutat
support
hypothesi
known
axi
regul
bh
endotheli
cell
overexpress
gfrp
reduc
basal
bh
level
attenu
rise
bh
occur
respons
proinflammatori
stimulu
addit
primari
sourc
bh
appear
deriv
local
within
vascular
endothelium
gfrp
coexpress
within
cell
final
oral
lphe
elicit
rise
vascular
bh
effect
absent
mice
lack
endotheli
legend
supplement
tabl
previous
describ
combin
purifi
recombin
gfrp
protein
higher
basal
activ
alon
vitro
addit
lphe
mmol
l
effect
purifi
activ
alon
caus
signific
rise
activ
coincub
gfrp
confirm
lphe
alloster
regul
complex
figur
vivo
oral
lphe
mg
kg
bolu
wki
shr
significantli
increas
plasma
bh
level
within
min
level
return
back
baselin
within
h
figur
correspondingli
signific
rise
nitrit
level
also
detect
within
min
wherea
return
baselin
wki
remain
elev
shr
least
h
figur
interestingli
statist
signific
differ
bh
biopterin
group
although
trend
increas
observ
figur
restor
wki
valu
follow
shortterm
bolu
longterm
lphe
treatment
figur
anticip
superoxid
level
higher
basal
shr
compar
wki
figur
bolu
dose
longterm
administr
lphe
significantli
reduc
superoxid
level
shr
figur
superoxid
dismutas
posit
control
reduc
superoxid
studi
group
figur
observ
signific
chang
bh
biopterin
aortic
tissu
ae
lphe
administr
figur
unfortun
aortic
tissu
nitrit
level
fell
limit
detect
therefor
quantifi
confirm
lphe
absorb
follow
oral
gavag
figur
supplement
tabl
detect
signific
rise
lpheltyr
ratio
anim
treat
longterm
lphe
surpris
longterm
ad
libitum
lphe
dose
much
lower
dose
shortterm
bolu
dose
challeng
although
trend
decreas
dopamin
increas
adrenalin
noradrenalin
shr
wki
reach
statist
signific
tissu
except
heart
adrenalin
noradrenalin
level
significantli
higher
shr
wki
basal
equal
wki
level
follow
lphe
treatment
figur
aortic
ring
intact
denud
endothelium
follow
shortterm
incub
mmol
l
lphe
data
repres
mean
ae
sem
n
anim
triplicateanim
mesenter
arteri
aortic
ring
p
p
whole
curv
tabl
e
show
ec
valu
nmol
l
compar
salin
control
lphe
treatment
studi
data
repres
mean
ec
valu
ae
sem
n
independ
experi
p
p
ach
acetylcholin
ec
effect
concentr
maxim
respons
abbrevi
figur
heikal
et
al
importantli
proofofconcept
studi
demonstr
ration
therapeut
target
vascular
dysfunct
henc
develop
lphe
mimet
select
bind
enhanc
protein
complex
may
clinic
valu
data
suggest
lphe
could
translat
clinic
given
minim
effect
observ
catecholamin
advanc
caution
given
lphe
divers
biolog
action
potenti
predict
advers
drug
reaction
bind
gfrp
form
protein
complex
recept
alloster
regul
lphe
feed
forward
bh
feedback
regul
result
confirm
numer
previou
report
lphe
enhanc
activ
bound
gfrp
addit
essenti
cofactor
role
no
activ
bh
also
requir
phenylalanin
hydroxylas
catalyz
convers
lphe
ltyr
convert
dopamin
adrenalin
noradrenalin
lphe
thu
regul
metabol
via
feedforward
activ
subsequ
increas
bh
henc
phenylalanin
hydroxylas
activ
import
sustain
elev
lphe
becom
neurotox
inde
bh
success
use
treatment
subset
patient
phenylketonuria
consist
rais
biopterin
level
seen
patient
lphe
load
previou
observ
mice
verifi
whether
lphe
could
activ
axi
function
seri
studi
carri
use
fresh
conduit
aortic
resist
mesenter
blood
vessel
wki
shr
consist
publish
report
achmedi
vascular
relax
shr
significantli
impair
comparison
wki
rat
shortterm
lphe
incub
within
organ
bath
significantli
improv
vascular
relax
shr
vessel
yet
effect
wki
impli
lphe
via
local
elev
bh
within
vasculatur
enhanc
bioavail
endotheli
function
circumst
pathway
dysfunct
consist
differenti
effect
plasma
nitrit
shr
wki
discuss
preced
text
interestingli
lphe
pronounc
effect
vascular
relax
mesenter
thu
still
much
work
undertaken
improv
efficaci
safeti
pharmacotherapi
enhanc
bioavail
present
studi
provid
first
proofofconcept
data
complex
ration
therapeut
target
achiev
bh
elev
restor
within
blood
vessel
translat
find
propos
parallel
research
strategi
first
clinic
devel
howev
assess
lvef
variabl
limit
abil
detect
earli
cardiotox
mani
patient
histolog
evid
cardiotox
decrement
systol
function
occur
importantli
reduct
lvef
often
irrevers
side
effect
dox
therapi
recov
systol
function
despit
receiv
optim
medic
therapi
earli
detect
method
anthracyclineinduc
cardiotox
preced
decrement
lvef
propos
howev
limit
inconsist
data
exist
regard
efficaci
approach
precis
mechan
doxinduc
cardiotox
fulli
elucid
although
well
establish
dox
induc
cardiotox
larg
excess
product
reactiv
oxygen
speci
ro
lead
direct
myocardi
apoptosi
contractil
abnorm
inflamm
vascular
injuri
promot
deleteri
cardiac
remodel
increas
activ
abund
matrix
metalloproteinas
mmp
studi
report
elev
circul
biomark
oxid
stress
myeloperoxidas
preced
clinic
signific
systol
dysfunct
anthracyclinetr
patient
ct
imag
use
local
heart
confirm
epicardi
surfac
voi
edg
placement
standard
uptak
valu
suv
calcul
lv
myocardium
liver
lv
blood
pool
differ
blood
pool
liver
suv
observ
group
see
later
text
therefor
ro
activ
ratio
determin
ratio
lv
myocardi
suv
lv
blood
pool
suv
account
differ
tissu
tracer
clearanc
bioavail
result
quantit
analysi
tunelposit
stain
rat
shown
figur
unlik
observ
progress
histopatholog
chang
describ
preced
text
cellular
apoptosi
trend
increas
doxtreat
rat
week
compar
timematch
control
rat
p
significantli
increas
compar
doxtreat
rat
week
p
figur
major
find
present
studi
respons
activ
cal
cardiac
myocyt
isol
treat
mice
use
measur
mitochondri
membran
potenti
j
describ
previous
flavoprotein
autofluoresc
use
measur
flavoprotein
oxid
base
previous
describ
method
detail
method
provid
supplement
method
figur
chang
j
observ
agematch
mdx
myocyt
figur
figur
alter
observ
agematch
mdx
myocyt
figur
howev
myocyt
isol
mdx
mice
treat
either
pmo
dose
regimen
exhibit
signific
increas
flavoprotein
oxid
respons
bayk
figur
treatment
regimen
rescu
respons
bayk
significantli
alter
flavoprotein
oxid
wt
mdx
myocyt
figur
mitochondri
electron
transport
chain
uncoupl
carbonyl
trifluoromethoxi
phenylhydrazon
increas
flavoprotein
signal
confirm
signal
mitochondri
origin
figur
data
indic
treatment
precardiomyopath
mdx
mice
shortterm
highdos
pmo
treatment
regimen
restor
metabol
activ
mdx
heart
figur
also
examin
efficaci
longterm
highdos
pmo
treatment
regimen
restor
j
isol
cardiac
myocyt
calciumfre
condit
bayk
elicit
signific
increas
j
wt
myocyt
attenu
nisoldipin
figur
alter
observ
agematch
mdx
myocyt
figur
howev
treatment
mdx
mice
mgkg
pmo
per
week
week
complet
rescu
respons
figur
respons
attenu
nisoldipin
figur
bayk
significantli
alter
j
wt
mdx
myocyt
figur
oligomycin
induc
signific
increas
fluoresc
mdx
myocyt
demonstr
week
abbrevi
figur
also
investig
efficaci
longterm
highdos
pmo
treatment
regimen
metabol
activ
bayk
caus
signific
increas
flavoprotein
oxid
myocyt
wt
mice
prevent
nisoldipin
figur
alter
observ
agematch
mdx
myocyt
figur
figur
respons
also
attenu
mitochondri
calcium
uniport
mitochondri
calcium
uptak
blocker
ryanodin
receptor
sarcoplasm
reticulum
calcium
releas
blocker
dantrolen
figur
alter
observ
agematch
mdx
myocyt
figur
howev
myocyt
isol
mdx
mice
treat
pmo
exhibit
signific
increas
metabol
activ
respons
bayk
could
attenu
nisoldipin
dantrolen
figur
bayk
significantli
alter
metabol
activ
wt
mdx
pmotreat
mdx
myocyt
figur
oligomycin
induc
signific
decreas
metabol
activ
myocyt
demonstr
myocyt
metabol
activ
figur
figur
week
differ
longer
signific
subsequ
phase
doubleblind
placebocontrol
studi
involv
prolong
treatment
dmd
patient
mgkgweek
week
improv
ambul
walk
test
secondari
assess
motor
function
furthermor
advers
event
includ
kidney
liver
toxic
like
offtarget
effect
omethyl
phosphorothio
backbon
report
patient
figur
prevent
develop
cardiomyopathi
importantli
toxic
vivo
figur
consist
previou
studi
find
pmo
treatment
result
accumul
littl
normal
dystrophin
protein
express
mdx
mice
figur
importantli
suffici
result
function
improv
mdx
heart
figur
use
mdx
mous
model
dmd
previous
patient
lifethreaten
sever
debilit
diseas
wait
approv
simpli
long
abolish
hope
diseas
quickli
fatal
lead
sustain
even
perman
disabl
whose
diseas
linger
without
effect
proven
therapi
note
although
term
compassion
use
preapprov
access
often
use
inform
refer
use
investig
drug
treat
patient
outsid
clinic
trial
term
defin
describ
fda
regul
simpli
refer
expand
access
investig
drug
call
ea
limit
individu
patient
advocaci
organ
press
group
patient
rare
andor
orphan
diseas
exampl
abl
access
promis
new
therapi
prior
approv
inde
social
media
increasingli
becom
consumerpati
advocaci
tool
implement
fda
regulatori
chang
promot
access
investig
therapeut
addit
drug
complet
phase
test
await
approv
patient
compani
also
express
concern
data
compassion
use
may
appli
cmv
infect
later
studi
also
show
ganciclovir
patient
live
longer
fda
refus
approv
ganciclovir
treatment
cmv
retin
anim
studi
use
signific
human
placebocontrol
trial
base
market
applic
mani
question
whether
use
ganciclovir
wise
safe
ganciclovir
known
efficaci
becam
paradox
imposs
carri
human
control
trial
trial
ethic
justifi
investig
honestli
uncertain
whether
net
posit
benefit
placebo
exist
furthermor
neither
patient
doctor
will
risk
assign
placebo
loss
eyesight
result
publish
syntex
sought
approv
studi
ganciclovir
treatment
cmv
coliti
know
market
approv
drug
obtain
fda
rule
would
allow
offlabel
use
retin
potenti
benefit
must
justifi
potenti
risk
treatment
provid
treatment
must
compromis
interfer
ongo
fda
drug
develop
program
critic
deplet
limit
suppli
investig
drug
also
need
ongo
studi
futur
studi
plan
stage
immedi
lifethreaten
condit
diseas
defin
fda
stage
diseas
reason
likelihood
death
occur
within
matter
month
prematur
death
like
without
earli
treatment
seriou
diseas
condit
defin
associ
morbid
substanti
impact
daytoday
function
furthermor
shortliv
selflimit
morbid
usual
suffici
qualifi
condit
morbid
need
irrevers
provid
persist
recurr
fda
state
whether
condit
seriou
matter
clinic
judgment
base
impact
factor
surviv
daytoday
function
likelihood
diseas
left
untreat
progress
less
sever
condit
seriou
one
anim
speci
cat
armadillo
guinea
pig
swine
ferret
thalidomid
test
teratogen
effect
induc
occasion
fact
human
birth
defect
began
appear
offspr
women
ingest
thalidomid
pregnanc
sed
treat
nausea
research
point
thalidomid
fail
demonstr
teratogen
rat
first
insist
thalidomid
could
culprit
germani
drug
first
develop
thalidomid
held
safe
prescript
requir
use
advertis
use
pregnant
women
drug
compani
distribut
free
sampl
factori
employe
product
approv
anim
rule
issu
quickli
guidanc
publish
tabl
reason
wellunderstood
pathophysiolog
mechan
toxic
toxic
substanc
prevent
substanti
reduct
product
effect
demonstr
anim
speci
expect
react
respons
predict
human
unless
effect
demonstr
singl
anim
speci
repres
suffici
wellcharacter
anim
model
predict
respons
human
anim
studi
endpoint
clearli
relat
desir
benefit
human
gener
enhanc
surviv
prevent
major
morbid
data
inform
kinet
pharmacodynam
product
relev
data
inform
anim
human
allow
select
effect
dose
human
relationship
mortal
intens
glycem
control
seen
patient
heart
failur
whose
diabet
manag
use
noninsulindepend
therapeut
regimen
develop
heart
failur
common
state
hyperinsulinemia
state
glucos
intoler
accompani
defici
insulin
find
support
find
allow
user
access
inform
contain
display
glanc
equival
capabl
achiev
use
biocular
display
display
provid
differ
imag
provid
stereoscop
imag
pair
hmd
platform
gener
imag
pair
use
panel
display
small
projector
seri
optic
enlarg
imag
simul
project
distanc
eas
focus
illustr
sever
common
system
figur
given
project
distanc
resolut
percept
depth
influenc
distanc
eye
converg
focal
distanc
eye
refer
vergenc
left
accommod
right
respect
display
reli
stereo
vision
influenc
vergenc
adjust
stereo
dispar
left
right
eye
focal
plane
optic
remain
fix
eye
bottom
perceiv
vergenc
depth
imag
sphere
display
distanc
intersect
display
imag
right
accommod
distanc
distanc
focal
plane
cube
focu
object
closer
farther
focal
distanc
appear
focu
vergenc
accommod
conflict
caus
discomfort
due
disagr
vergenc
accommod
distanc
particularli
close
distanc
accommod
cue
influenti
silva
et
al
extend
realiti
platform
constrain
primarili
cost
size
weight
power
achiev
highest
visual
qualiti
mobil
process
speed
interact
visual
qualiti
depend
resolut
bright
focal
depth
fov
display
technolog
demand
aspect
extend
realiti
gener
largest
design
cost
constraint
system
compound
requir
stereoscop
pair
imag
gener
percept
depth
vergenc
angular
dispar
display
figur
left
display
system
must
compromis
size
cost
provid
maximum
visual
qualiti
match
capabl
human
visual
system
hv
depth
close
distanc
also
perceiv
accommod
figur
right
percept
depth
due
dispar
focal
depth
challeng
face
convent
stereoscop
display
accommod
requir
allow
user
focu
instrument
digit
object
simul
distanc
eg
surgic
guidanc
overlay
within
person
space
action
space
dispar
vergenc
depth
display
hmd
accommod
expect
hv
refer
vergenc
accommod
conflict
vac
respons
discomfort
close
work
distanc
display
system
support
singl
fix
focal
plane
digit
element
figur
although
emerg
technolog
provid
multipl
fix
focal
plane
employ
adapt
optic
everi
design
decis
mitig
challeng
affect
applic
use
procedur
environ
ar
mxr
display
provid
best
compromis
digit
annot
clear
fov
high
pixel
densiti
larg
fov
devic
design
desktop
offic
use
requir
umbil
highpow
workstat
support
process
requir
display
devic
provid
larger
digit
display
higherresolut
display
expens
complic
setup
procedur
limit
devic
potenti
provid
physician
steril
interfac
allow
control
imag
earli
data
show
improv
visual
allow
physician
learn
quickli
interpret
imag
accur
accomplish
intervent
less
time
improv
physician
perform
base
better
inform
like
translat
lowercost
procedur
better
outcom
patient
peter
libbi
md
associ
editor
jacc
basic
translat
scienc
term
translat
research
trip
lightli
tongu
actual
practic
often
prove
elus
argu
partnership
prove
pivot
promot
translat
laboratori
studi
advanc
clinic
medicin
focu
particularli
defin
horizont
vertic
partnership
horizont
partnership
pertain
relationship
laboratori
investig
patientbas
clinicallyori
particip
biomed
enterpris
vertic
partnership
refer
interact
academ
investig
involv
biotechnolog
pharmaceut
enterpris
